French Grand Est region: Braintale presents promising results on Amyotrophic
Lateral Sclerosis and announces a partnership with the University Hospitals of

PDF version

Braintale, a medtech from Paris Hospitals, accelerates its development in the French Grand Est region
with the presentation in Strasbourg of the results of its exploratory study on the relevance of its
clinically validated biomarkers platform for diagnosis and follow-up of patients with amyotrophic
lateral sclerosis (ALS or Charcot disease) and the announcement of the signing of a strategic partnership
with the University Hospitals of Strasbourg.

On the occasion of the Journées de Neurologie en Langue Française in Strasbourg, Braintale, the French
white matter specialist, presents first encouraging results on the value of its white matter quantification
platform for early detection of amyotrophic lateral sclerosis, offering better monitoring of disease
progression and also potentially in the long term the possibility to increase the chances of success of clinical
developments by precisely identifying the different sub-forms of the disease and helping to evaluate the
effectiveness of drug candidates. Long underestimated in neurosciences, white matter represents 80% of
our brain, playing a key role in its proper functioning, development, and aging, whether normal or
pathological. The careful examination of white matter can become a game-changer for many diseases
including Amyotrophic lateral sclerosis.

What is Amyotrophic Lateral Sclerosis?

Amyotrophic lateral sclerosis (ALS), also known as Charcot’s disease, is characterized by a progressive and
irreversible degeneration of motor neurons that allow the body’s movements to be controlled. Patients
with ALS gradually experience symptoms such as cramps, muscle contractions, and strain. Over time, within
two to five years of initial diagnosis, the whole body is paralyzed, including the respiratory muscles,
resulting in inevitable death. Fatal in 100% of cases, the disease affects 50,000 patients in Europe*.
Today, doctors deplore a late and long journey to precisely diagnose the condition an average of one year
after the first symptoms, thus delaying the time to initiate symptomatic care, largely suboptimal.

How can Braintale be a game-changer?

BrainTale is now convinced that accurate and regular analysis of white matter can become a decisive
indicator in the management of patients with neurological diseases, notably ALS beyond the benefits
demonstrated in intensive care.
In the case of ALS, literature data highlight white matter alterations even before the onset of symptoms
and is, moreover, correlated precisely to clinical score and progression of the disease. The Braintale-care
platform, a CE marked digital medical device, is already available in selected centers. Non-invasive and
easily implementable in hospitals, the BrainTale-care platform can therefore become a decisive tool for
healthcare professionals in disease management.

The preliminary study presented today offers encouraging perspective in the diagnosis and disease
monitoring for ALS patients.

“This data in amyotrophic lateral sclerosis strengthens our approach in the potential of our platforms to
provide patients with concrete, innovative and relevant solutions”, comments Vincent Perlbarg, co-founder
and CSO of BrainTale. This study, conducted under the direction of Dr Pierre-François Pradat, neurologist
at the Pitié-Salpêtrière Hospital in Paris, is the result of the SOM-ALS Inserm-sponsored trial (NCT03694132)
and presented by Hugo Kermorvant. The poster is entitled Evaluation of a clinically validated MRI analysis
web platform for obtaining biomarkers in ALS and is available here: >> Posters >> Sclérose
latérale amyotrophique.
“These encouraging results are a strong signal to highlight the value of innovative neuroimaging tools for
the management of patients with ALS”, said Dr. Pradat. “Having to be confirmed on broader cohorts, this is
a significant opportunity to change the situation in disease management”, he adds.

A strategic partnership with the Strasbourg University Hospitals
Strasbourg University Hospitals have been convinced of Braintale’s platforms value, becoming the first nonparisian institution equipped with the Braintale-care platform. The platform, with its two CE-marked
modules under the Medical Device Regulation (MDR) in force in the European Community – brainQuant
and brainScore coma – are thus available to clinicians to offer optimal patient management.
Professor Julien Pottecher, anesthesiologist at the University Hospitals of Strasbourg comments “The
clinical interest of the Braintale-care platform and its expected benefits for patient management convinced
us to establish this strategic relationship with Braintale. This digital innovation in intensive care could
significantly change the situation in hospitals”.
“Braintale continues to shift imaging towards diagnosis and clinical prediction, opening up opportunities to
contribute alongside other practitioners to optimal patient management”, adds Professor Stéphane
Kremer, neurologist.

Julie Rachline, co-founder and president of LallianSe, Braintale’s CEO”the combination of these encouraging
results presented today in Strasbourg and the deployment of our solutions at Strasbourg University
Hospitals is for BrainTale a key step in our ambitious trajectory”.

*(Epidemiology of amyotrophic lateral sclerosis: an update of… : Current Opinion in Neurology (, What is ALS? | EUpALS ;

About the University Hospitals of Strasbourg
Alsace’s largest employer, the HUS are composed of five establishments. They ensure a mission of care but also of
research and teaching. Their specificity as Regional University Hospital (CHRU) They are able to provide routine
care to the population of Strasbourg and its surroundings as well as take charge of patients with complex or rare
diseases from more distant geographical areas.

About BrainTale
Braintale is an innovative company dedicated to the decryption of white substance to allow better management in
neurology and resuscitation with clinically validated prognostic solutions. With sensitive and reliable measurements
of white matter microstructure alterations, Braintale offers a digital biomarker platform to help in clinical decisionmaking. Braintale allows identification of patients at risk, early diagnosis and monitoring of disease progression and
treatment effectiveness. Based on more than 15 years of development, BrainTale’s products are developed to meet
the medical needs and expectations of healthcare professionals and patients.
Since its creation in 2018, the company has implemented a comprehensive quality management system and is now
ISO 13485 certified 2016, with a suite of products available on the European market.
For more information, please visit

Braintale – Julie Rachline, CEO +33 6 62 42 03 58
Braintale Press – Anna Casal +33 6 50 61 55 71
HU Strasbourg Presse – Hélène Braeuner +33 3 88 11 64 12


BRAINTALE, whose head office is 11 rue de l’Académie 67000 – STRASBOURG, is registered in the Trade and Companies Register under number 840 995 138 RCS STRASBOURG

Last update : 09/19/2022